Bezuclastinib

Name: Bezuclastinib in Nonadvanced systemic mastocytosis: Effects of other drugs on Bezuclastinib
Published: 2026-09-14T15:39:06-04:00

Nonadvanced systemic mastocytosis

Manufacturer: Cogent Biosciences
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the second half of 2026
Last updated: September 17, 2026

Section

Product information and disease description Product description Product information Drug/Drug, drug/disease interactions

Effects of other drugs on Bezuclastinib

1 evidence topic · 1 source

SUMMIT protocol exclusion: recent strong CYP3A4 inhibition or induction

“Received strong CYP3A4 inhibitors or inducers within 14 days or 5 drug half-lives before the first dose of study drug” (opens the source at this quote in a new tab)